OncoXome
OncoXome is an innovative oncology startup dedicated to developing effective, targeted cancer treatments that respect patients' quality of life. They combine promising drug delivery systems with cutting-edge therapies to target widespread cancer cells, prevent resistance, and induce cancer cell death, all while limiting side effects. Their approach involves understanding cancer as a complex ecosystem and utilizing exosomes and gene editing to deliver targeted therapies. The company aims to revolutionize cancer treatment by addressing advanced cancers with versatile, effective, safe, and targeted solutions, ultimately improving clinical outcomes, prolonging survival, and enhancing quality of life for patients.
Industries
Nr. of Employees
small (1-50)
Products
Extracellular vesicle delivery platform
A natural extracellular vesicle–based delivery platform engineered to carry therapeutic payloads with preferential uptake by cancer cells and limited accumulation in non‑target organs.
Gene‑editing therapeutic platform
A gene‑editing treatment approach focused on targeted knockout of mutated oncogenes to induce rapid cancer cell death while minimizing effects on non‑target cells.
Extracellular vesicle delivery platform
A natural extracellular vesicle–based delivery platform engineered to carry therapeutic payloads with preferential uptake by cancer cells and limited accumulation in non‑target organs.
Gene‑editing therapeutic platform
A gene‑editing treatment approach focused on targeted knockout of mutated oncogenes to induce rapid cancer cell death while minimizing effects on non‑target cells.
Expertise Areas
- Extracellular vesicle engineering
- Gene‑editing therapeutics (targeted knockout)
- Targeted drug delivery to tumors and metastases
- Preclinical oncology research and target validation
Key Technologies
- Extracellular vesicle (exosome) delivery
- Gene editing (targeted knockout approaches)
- Therapeutic nucleic acid payload design
- In vitro and in vivo tumor models